The development of MDA-7/IL-24 as a cancer therapeutic
- PMID: 20732354
- PMCID: PMC2947573
- DOI: 10.1016/j.pharmthera.2010.08.001
The development of MDA-7/IL-24 as a cancer therapeutic
Abstract
The cytokine melanoma differentiation associated gene 7 (mda-7) was identified by subtractive hybridization as a protein whose expression increased during the induction of terminal differentiation, and that was either not expressed or was present at low levels in tumor cells compared to non-transformed cells. Based on conserved structure, chromosomal location and cytokine-like properties, MDA-7, was classified as a member of the interleukin (IL)-10 gene family and designated as MDA-7/IL-24. Multiple studies have demonstrated that expression of MDA-7/IL-24 in a wide variety of tumor cell types, but not in corresponding equivalent non-transformed cells, causes their growth arrest and rapid cell death. In addition, MDA-7/IL-24 has been noted to radiosensitize tumor cells which in part is due to the generation of reactive oxygen species (ROS) and ceramide that cause endoplasmic reticulum stress and suppress protein translation. Phase I clinical trial data has shown that a recombinant adenovirus expressing MDA-7/IL-24 (Ad.mda-7 (INGN-241)) was safe and had measurable tumoricidal effects in over 40% of patients, strongly arguing that MDA-7/IL-24 could have significant therapeutic value. This review describes what is presently known about the impact of MDA-7/IL-24 on tumor cell biology and its potential therapeutic applications.
Copyright © 2010 Elsevier Inc. All rights reserved.
Figures



Similar articles
-
MDA-7/IL-24 as a cancer therapeutic: from bench to bedside.Anticancer Drugs. 2010 Sep;21(8):725-31. doi: 10.1097/CAD.0b013e32833cfbe1. Anticancer Drugs. 2010. PMID: 20613485 Free PMC article. Review.
-
MDA-7/IL-24 regulates proliferation, invasion and tumor cell radiosensitivity: a new cancer therapy?J Cell Biochem. 2005 Jul 1;95(4):712-9. doi: 10.1002/jcb.20502. J Cell Biochem. 2005. PMID: 15880678 Review.
-
mda-7/IL-24: multifunctional cancer-specific apoptosis-inducing cytokine.Pharmacol Ther. 2006 Sep;111(3):596-628. doi: 10.1016/j.pharmthera.2005.11.005. Epub 2006 Feb 7. Pharmacol Ther. 2006. PMID: 16464504 Free PMC article. Review.
-
Recent insights into apoptosis and toxic autophagy: The roles of MDA-7/IL-24, a multidimensional anti-cancer therapeutic.Semin Cancer Biol. 2020 Nov;66:140-154. doi: 10.1016/j.semcancer.2019.07.013. Epub 2019 Jul 26. Semin Cancer Biol. 2020. PMID: 31356866 Free PMC article. Review.
-
mda-7/IL-24, novel anticancer cytokine: focus on bystander antitumor, radiosensitization and antiangiogenic properties and overview of the phase I clinical experience (Review).Int J Oncol. 2007 Nov;31(5):985-1007. Int J Oncol. 2007. PMID: 17912425 Review.
Cited by
-
Insulin-like growth factor binding protein-3 mediates interleukin-24-induced apoptosis through inhibition of the mTOR pathway in prostate cancer.Oncol Rep. 2015 Nov;34(5):2273-81. doi: 10.3892/or.2015.4201. Epub 2015 Aug 13. Oncol Rep. 2015. PMID: 26323436 Free PMC article.
-
Adenovirus arming human IL-24 inhibits neuroblastoma cell proliferation in vitro and xenograft tumor growth in vivo.Tumour Biol. 2013 Aug;34(4):2419-26. doi: 10.1007/s13277-013-0792-1. Epub 2013 Apr 23. Tumour Biol. 2013. PMID: 23609032
-
Cancer targeting gene-viro-therapy for pancreatic cancer using oncolytic adenovirus ZD55-IL-24 in immune-competent mice.Mol Biol Rep. 2013 Sep;40(9):5397-405. doi: 10.1007/s11033-013-2638-8. Epub 2013 May 11. Mol Biol Rep. 2013. PMID: 23666064
-
In silico design of two novel fusion proteins, p28-IL-24 and p28-M4, targeted to breast cancer cells.Res Pharm Sci. 2020 May 11;15(2):200-208. doi: 10.4103/1735-5362.283820. eCollection 2020 Apr. Res Pharm Sci. 2020. PMID: 32582360 Free PMC article.
-
Insights into the Mechanisms of Action of MDA-7/IL-24: A Ubiquitous Cancer-Suppressing Protein.Int J Mol Sci. 2021 Dec 22;23(1):72. doi: 10.3390/ijms23010072. Int J Mol Sci. 2021. PMID: 35008495 Free PMC article. Review.
References
-
- Bursch W. The autophagosomal ± lysosomal compartment in programmed cell death. Cell Death and Differ. 2001;8:569–581. - PubMed
-
- Caudell EG, Mumm JB, Poindexter N, Ekmekcioglu S, Mhashilkar AM, Yang XH, et al. The protein product of the tumor suppressor gene, melanoma differentiation-associated gene 7, exhibits immunostimulatory activity and is designated IL-24. J Immunol. 2002;168:6041–6046. - PubMed
-
- Chada S, Mhashilkar AM, Ramesh R, Mumm JB, Sutton RB, Bocangel D, et al. Bystander activity of Ad-mda7: human MDA-7 protein kills melanoma cells via an IL-20 receptor-dependent but STAT3-independent mechanism. Mol Ther. 2004a;10:1085–1095. - PubMed
-
- Chada S, Sutton RB, Ekmekcioglu S, Ellerhorst J, Mumm JB, Leitner WW, et al. MDA-7/IL-24 is a unique cytokine-tumor suppressor in the IL-10 family. Int Immunopharmacol. 2004b;4:649–667. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R01 CA108520/CA/NCI NIH HHS/United States
- P01-NS031492/NS/NINDS NIH HHS/United States
- R01 CA127641/CA/NCI NIH HHS/United States
- R01-CA077141/CA/NCI NIH HHS/United States
- R01 CA063753/CA/NCI NIH HHS/United States
- R01-DK52825/DK/NIDDK NIH HHS/United States
- R01 CA141703/CA/NCI NIH HHS/United States
- P01 CA104177/CA/NCI NIH HHS/United States
- R01 CA129111/CA/NCI NIH HHS/United States
- R01 CA098712/CA/NCI NIH HHS/United States
- P01-CA104177/CA/NCI NIH HHS/United States
- P01 NS031492/NS/NINDS NIH HHS/United States
- R01-CA098712/CA/NCI NIH HHS/United States
- R01-CA127641/CA/NCI NIH HHS/United States
- R01 CA122930/CA/NCI NIH HHS/United States
- R01 CA097318/CA/NCI NIH HHS/United States
- R01-CA108325/CA/NCI NIH HHS/United States
- R01-CA063753/CA/NCI NIH HHS/United States
- R01 DK052825/DK/NIDDK NIH HHS/United States
- R01-CA097318/CA/NCI NIH HHS/United States
- R01 CA150214/CA/NCI NIH HHS/United States
- R01 CA138587/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical